Catalent   1Q Revenues: $442.2 million (+5%) 1Q Earnings: $4.6 million (earnings were $11.7 million 1Q16) Comments: Revenue from the Softgel Technologies segment was $186.4 million, an increase of 1%. Revenue from the Drug Delivery Solutions segment was $191.3 million, up 10% primarily driven by volumes related to fee-for-service development and analytical testing in the U.S., the company’s biologics offering and European pre-filled syringe operations. This growth was partially offset by...